Applied Biosystems to Webcast Interview at Thomas Weisel Healthcare Conference on September 6.

FOSTER CITY, Calif. -- Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, announced today that it will participate in the Thomas Weisel Healthcare Conference on Thursday, September 6, 2007. The live webcast is scheduled to begin at 3:50 p.m. ET. Tony L. White, Chief Executive Officer, Applera Corporation and President, Applied Biosystems, and Kimberlee Caple, Vice President and General Manager of the High Throughput Discovery business unit, which is developing the Group's SOLiD[TM] next-generation sequencing platform, will be interviewed by a Thomas Weisel financial analyst and answer questions from the audience.

Interested parties may access the live webcast and replay by visiting the Investors section of the Applied Biosystems web site at http://ir.appliedbiosystems.com or the Investors & Media section of the Applera web site at www.applera.com. It is suggested that interested parties access the webcast 15 minutes before the start of the live webcast. The webcast replay will be archived on the Presentations page of the Investors section of each website.

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of approximately $2.1 billion during fiscal 2007. The Celera Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera maintains a strategic alliance with Abbott for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com.

(c)Copyright 2007. Applera Corporation. All Rights Reserved. AB (Design), Applied Biosystems, Applera, and Celera are registered trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.